Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAXOZOL
- Development stage
- Phase 4
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Drug Delivery Systems
- Administration
- Oral
01
Overview
NAXOZOL is a combination drug designed to provide sequential delivery of naproxen and esomeprazole strontium. It consists of an enteric-coated naproxen 500 mg core followed by a non-enteric-coated, immediate-release esomeprazole strontium tetrahydrate 20 mg mantle. This formulation is primarily used for treating osteoarthritis and other rheumatic diseases while reducing the risk of gastrointestinal complications associated with non-steroidal anti-inflammatory drug (NSAID) use.
- Brand names
- NAXOZOL
- Other names
- naproxen + esomeprazole strontium tetrahydratenaproxen + esomeprazole
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on NAXOZOL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAXOZOL.